CholestasisDoc
@cholestasisdoc.bsky.social
Hospital doctor, with interests in liver medicine, transplantation and inflammatory bowel disease. Combat sports’ enthusiast, and occasional stand up comic.
Reposted by CholestasisDoc
Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians
September 11, 2025 at 3:00 PM
Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians
Reposted by CholestasisDoc
🆕 Global Commission proposes overhaul of obesity diagnosis – going beyond BMI to define when obesity is a disease.
Find out more: hubs.li/Q030v_j_0
Find out more: hubs.li/Q030v_j_0
January 15, 2025 at 7:53 AM
🆕 Global Commission proposes overhaul of obesity diagnosis – going beyond BMI to define when obesity is a disease.
Find out more: hubs.li/Q030v_j_0
Find out more: hubs.li/Q030v_j_0
Reposted by CholestasisDoc
New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
www.thelancet.com/journals/lan...
#GastroSky #OncSky #MedSky @oncoalert.bsky.social
www.thelancet.com/journals/lan...
#GastroSky #OncSky #MedSky @oncoalert.bsky.social
January 15, 2025 at 6:07 AM
New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
www.thelancet.com/journals/lan...
#GastroSky #OncSky #MedSky @oncoalert.bsky.social
www.thelancet.com/journals/lan...
#GastroSky #OncSky #MedSky @oncoalert.bsky.social
Reposted by CholestasisDoc
Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven...
doi.org
January 7, 2025 at 7:30 AM
Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social
New from us: our trial protocol for faecal microbiota transplantation to treat people living with PSC and IBD.
Actively recruiting!
@bhmullish.bsky.social @nabilquraishi.bsky.social @alanmcn1.bsky.social @pscsupport.bsky.social
bmjopen.bmj.com/content/bmjo...
Actively recruiting!
@bhmullish.bsky.social @nabilquraishi.bsky.social @alanmcn1.bsky.social @pscsupport.bsky.social
bmjopen.bmj.com/content/bmjo...
bmjopen.bmj.com
January 7, 2025 at 10:27 AM
New from us: our trial protocol for faecal microbiota transplantation to treat people living with PSC and IBD.
Actively recruiting!
@bhmullish.bsky.social @nabilquraishi.bsky.social @alanmcn1.bsky.social @pscsupport.bsky.social
bmjopen.bmj.com/content/bmjo...
Actively recruiting!
@bhmullish.bsky.social @nabilquraishi.bsky.social @alanmcn1.bsky.social @pscsupport.bsky.social
bmjopen.bmj.com/content/bmjo...
Agree that mRNA vaccine technology needs deeper evaluation. @fda.gov should provide further details in due course.
www.bmj.com/content/387/...
www.bmj.com/content/387/...
FDA pauses all infant RSV vaccine trials after rise in severe illnesses
The US Food and Drug Administration (FDA) has put on hold all respiratory syncytial virus (RSV) vaccine trials involving infants (aged under 2 years) or RSV naive children aged 2-5 years, after a tria...
www.bmj.com
December 26, 2024 at 2:14 PM
Agree that mRNA vaccine technology needs deeper evaluation. @fda.gov should provide further details in due course.
www.bmj.com/content/387/...
www.bmj.com/content/387/...
New work from us:
Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features.
academic.oup.com/ecco-jcc/adv...
Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features.
academic.oup.com/ecco-jcc/adv...
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
academic.oup.com
December 14, 2024 at 1:18 PM
New work from us:
Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features.
academic.oup.com/ecco-jcc/adv...
Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features.
academic.oup.com/ecco-jcc/adv...
Reposted by CholestasisDoc
Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
academic.oup.com
December 14, 2024 at 11:53 AM
Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky